Mahon Paul A, executive vice president and general counsel of United Therapeutics (NASDAQ: UTHR) Corp, exercised options for 8,300 shares at $146.03 per share on 3 September 2026. He then sold the same number of United Therapeutics shares in 11 transactions, with sale prices …
The ranks of the world's billionaires hit a record 3,795 people in 2025 as the artificial intelligence boom turbocharged wealth creation across the globe, according to a report published by wealth intelligence firm Altrata. The finding marks an 8.2% increase in billionaire headcount, the …
Joby Aviation, Inc. (NYSE: JOBY) director Sciarra Paul Cahill sold 62,500 shares at $6.68 per share. The transaction took place on Sep. 2, 2026, leaving Cahill with 55,703,057 shares after the sale.
The global bond rout is raising borrowing costs across the economy, forcing governments, companies and consumers to confront the possibility that expensive debt is here to stay. Governments are among those most exposed to the rise in yields, according to analysts, since sovereign debt …
Privia Health Group, Inc. (NASDAQ: PRVA) awarded director Ernest Opella Finley 6,350 shares on September 1, 2026. The shares were issued at $0 per share, and Finley’s resulting ownership totaled 6,350 shares.
Pulmonx Corp (NASDAQ: LUNG) Chief Commercial Officer Rose Geoffrey Beran sold 7,879 shares at $2.26 per share across four transactions. Following the transactions, Beran owned 449,832 shares.
REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) director Kathryn Guarini exercised options for 400 shares at $719.37 per share on Sept. 2, 2026. The transaction left Guarini with 1,003 shares.
REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) executive McCourt Marion sold 2,346 shares at prices ranging from $850 to $857.39 per share. The EVP Commercial completed the sales in two transactions spanning Sep. 2 and Sep. 3, 2026.
REGENXBIO Inc. (NASDAQ: RGNX) recorded the forfeiture of 234 shares at $9.32 per share by Chief Technology Officer Malzahn Craig on September 1, 2026. His reported ownership after the transaction stood at 81,960 shares.
REGENXBIO Inc. (NASDAQ: RGNX) recorded the forfeiture of 234 shares at $9.32 per share by Chief Technology Officer Malzahn Craig on September 1, 2026. His reported ownership after the transaction stood at 81,960 shares.